Clinical observation on palipeddone sustained release tablet in the treatment of schizophrenia

Dian Zhang Xiong; Yu Ru Yuan; Rong Gao; Qing Wang; Wen Pin Chang

doi:10.1007/BF03379733

Clinical observation on palipeddone sustained release tablet in the treatment of schizophrenia

Dian Zhang Xiong, Yu Ru Yuan, Rong Gao, Qing Wang, Wen Pin Chang

Department of Occupational Therapy

Research output: Contribution to journal › Article › peer-review

Abstract

Objective of this study was to evaluate the efficacy and adverse drug reactions (ADR) of palipeddone sustained release tablet in the treatment of schizophrenia in outpatients. Outpatients with schizophrenia treated with palipeddone sustained release tablet (observation group) in our hospital from Apr. to Sep. in 2009 were followed up and compared with those treated with risperidone (control group) during the same period. PANSS and TESS were applied to evaluate efficacy and ADR. Results suggest that the cure rates were 42.4% for control group and 49.6% for observation group. The effective rates were 74.8% for control group and 80.3% for observation group (P

Original language	English (US)
Pages (from-to)	146-150
Number of pages	5
Journal	Activitas Nervosa Superior
Volume	55
Issue number	4
DOIs	https://doi.org/10.1007/BF03379733
State	Published - 2013

All Science Journal Classification (ASJC) codes

Neurology
Clinical Neurology
Cognitive Neuroscience
Psychiatry and Mental health
Biological Psychiatry
Behavioral Neuroscience

Access to Document

10.1007/BF03379733

Fingerprint Dive into the research topics of 'Clinical observation on palipeddone sustained release tablet in the treatment of schizophrenia'. Together they form a unique fingerprint.

Cite this

@article{4a03437bb2e149b689ca94d70c9b3db8,

title = "Clinical observation on palipeddone sustained release tablet in the treatment of schizophrenia",

abstract = "Objective of this study was to evaluate the efficacy and adverse drug reactions (ADR) of palipeddone sustained release tablet in the treatment of schizophrenia in outpatients. Outpatients with schizophrenia treated with palipeddone sustained release tablet (observation group) in our hospital from Apr. to Sep. in 2009 were followed up and compared with those treated with risperidone (control group) during the same period. PANSS and TESS were applied to evaluate efficacy and ADR. Results suggest that the cure rates were 42.4% for control group and 49.6% for observation group. The effective rates were 74.8% for control group and 80.3% for observation group (P",

author = "Xiong, {Dian Zhang} and Yuan, {Yu Ru} and Rong Gao and Qing Wang and Chang, {Wen Pin}",

year = "2013",

doi = "10.1007/BF03379733",

language = "English (US)",

volume = "55",

pages = "146--150",

journal = "Activitas Nervosa Superior",

issn = "1802-9698",

publisher = "Neuroscientia",

number = "4",

}

TY - JOUR

T1 - Clinical observation on palipeddone sustained release tablet in the treatment of schizophrenia

AU - Xiong, Dian Zhang

AU - Yuan, Yu Ru

AU - Gao, Rong

AU - Wang, Qing

AU - Chang, Wen Pin

PY - 2013

Y1 - 2013

N2 - Objective of this study was to evaluate the efficacy and adverse drug reactions (ADR) of palipeddone sustained release tablet in the treatment of schizophrenia in outpatients. Outpatients with schizophrenia treated with palipeddone sustained release tablet (observation group) in our hospital from Apr. to Sep. in 2009 were followed up and compared with those treated with risperidone (control group) during the same period. PANSS and TESS were applied to evaluate efficacy and ADR. Results suggest that the cure rates were 42.4% for control group and 49.6% for observation group. The effective rates were 74.8% for control group and 80.3% for observation group (P

AB - Objective of this study was to evaluate the efficacy and adverse drug reactions (ADR) of palipeddone sustained release tablet in the treatment of schizophrenia in outpatients. Outpatients with schizophrenia treated with palipeddone sustained release tablet (observation group) in our hospital from Apr. to Sep. in 2009 were followed up and compared with those treated with risperidone (control group) during the same period. PANSS and TESS were applied to evaluate efficacy and ADR. Results suggest that the cure rates were 42.4% for control group and 49.6% for observation group. The effective rates were 74.8% for control group and 80.3% for observation group (P

UR - http://www.scopus.com/inward/record.url?scp=84893483606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893483606&partnerID=8YFLogxK

U2 - 10.1007/BF03379733

DO - 10.1007/BF03379733

M3 - Article

AN - SCOPUS:84893483606

VL - 55

SP - 146

EP - 150

JO - Activitas Nervosa Superior

JF - Activitas Nervosa Superior

SN - 1802-9698

IS - 4

ER -